Thakur, ShikhaAnsari, Arshad J.Joshi, Gaurav2024-01-212024-08-132024-01-212024-08-132022-10-149780443186165978044318617210.1016/B978-0-443-18616-5.00004-1http://10.2.3.109/handle/32116/3573The present chapter is a compilation and analysis of USFDA approved small drug candidates about fused pyrimidine pharmacophore. Out of 63 drugs approved so far, nearly 38% of drugs are approved for chemotherapeutic treatment of cancer. Further, antiviral category shares 19% followed by drugs for cardiovascular disorders (14%), inflammatory diseases (9%), respiratory disorders (6%), neurological disorders (5%), benign prostatic hypertrophy (3%), erectile dysfunction (2%), diabetes (2%) and thrombocytopenia (2%). The chapter further focuses on key biological targets affected by the reported drug and their pharmacological mechanism of action. We have also focused on elucidating key chemical taxonomy utilized in fused pharmacophores of pyrimidine. The analysis suggested purine nucleosides (11 drugs) and xanthines/hypoxanthines (11 drugs) share the major chunk utilized in drug development out of fused pyrimidine nucleus. � 2023 Elsevier Ltd. All rights reserved.en-USDrugDrug developmentDrug useFused pyrimidinesInterventionsPharmaceutical therapyPharmacodynamicsBook chapterhttps://linkinghub.elsevier.com/retrieve/pii/B9780443186165000041